Covid-19 Vaccine is here. Where can you still find Value in Biotech?

Pfizer (NYSE: PFE) just announced results that could pave the way for a covid-19 vaccine by year end.

An article in Bloomberg stated: “The Covid-19 vaccine being developed by Pfizer Inc. and BioNTech SEprevented more than 90% of infections in a study of tens of thousands of volunteers, the most encouraging scientific advance so far in the battle against the coronavirus.”

As of just a few weeks ago, the companies in the chart shown here were trialing 60 different drugs and vaccines and had 60 different drugs in development targeting covid-19.  Although Pfizer seems to be ahead of the curve, it might surprise you to know that most of the other contenders like AstraZeneca (NYSE: AZN), GlaxoSmithKline (NYSE: GSK), Merk & Co. (NYSE: MRK) and other majors are popping on the news.

So where is the value in Biotech post-covid-vaccine?

Have a look at PetVivo Holdings, Inc. (OTCQB: PETV).  The stock has recently moved from a low of about $.20 per share up to over $1.60 on increasing volume.  It looks like the stock could be in the process of being accumulated.

Currently the stock has only 24 million shares outstanding and a market cap of $40 million.

Back in July, the stock was given a target price of between $1.74 and $2.32 per share by Marble Arch Research.  You can download the full report here: – Among other results, the report states “At ~1x FY23 sales, the stock is substantially undervalued relative to its comps mostly trading in a comparable 3X-4X P/S multiple range.”

Goldman Research just announced a new report with its current target price under review.  You can see the report here:

PetVivo Holdings, Inc. (OTCQB: PETV) just announced that a company out of Orlando, Florida called nScryptthat designs and manufactures high-precision industrial Micro-dispensing and Direct Digital Manufacturing equipment, has just successfully 3D bio-printed PetVivo’s (OTCQB: PETV) biomaterial for orthopedic implants using its Bio-Fabrication Tool (BAT). To the best of the company’s knowledge, there is no other company that has the ability to provide these life-based components for the 3D printing marketplace.

The applications and cures for this technology are endless.  Implants, replacements, up until and including the present, have been made with foreign ingredients like titanium and other metals.  The future of this science now lies with the technology that allows for a more biologically familiar biomaterial.  PetVivo’s biomaterial is made from the same components as the body’s natural tissue, allowing cells to be added to the structures being printed.

Ultimately, this breakthrough could lead to the creation of implants that actually mimic the bone itself.

KUSH, PETV’s lead product is a veterinarian-administered intraarticular injection for the treatment of osteoarthritis in dogs and horses is scheduled for expanded commercial sales and the development of its proprietary mucoadhesive active agent delivery products.

Sales in the $4.8 billion dog and horse therapeutics market is expected to begin shortly.

Just recently a new successful Kush study came to light when Just 4 weeks ago, Fender Bender, a racehorse suffering from osteoarthritis, was put up for sale and claimed for $3,000.00 and the new owner treaded him with PetVivo’s Kush.  Fender Bender won at Canterbury Park on August 4, 2020. 

Pet Vivo Holdings, Inc. (OTCQB: PETV)’s new state of the art medical device manufacturing facility in Edina Minnesota, primarily dedicated to the manufacture of its veterinary medical device for the treatment of osteoarthritis (OA), KUSH™ will serve as the primary location for PetVivo medical device operations, which provides manufacturing capabilities to produce up to 500,000 syringes of Kush that could generate over $100 million in revenue annually.

PetVivo is an emerging biomedical device company leveraging the investments in the human biomaterials and medical device industries to commercialize therapeutics to pets.

Pet Vivo (OTCQB: PETV) also has a portfolio of 19 patents that protect the company’s pipeline of 16 products for the treatment of animals and people.

PetVivo is benefiting from trials on the human side with a lower barrier to approval for pets.

According to The American Pet Products Association, almost 85 million households have a pet and over the last 30 years pet ownership has gone from 56% to 68% of all households.

It seems that PetVivo has value here.  If you’re looking for a biotech that has not enjoyed a massive run yet, Pet Vivo may be the solution.